Viral Vectors and Plasmid DNA Manufacturing Market UpComing Developments With Major Key Players

Gene therapy and genetically modified therapies are promising treatment option, which includes introduction of a normal or functional copy of a gene in the defective cell. Gene therapy has capability to cure or prevent the progression of diseases, which include inherited disorders, cancers, cardiovascular diseases, neurological disorder, and infectious pathogen. There are number of systems showing efficient transfer of therapeutics gene into the target cells, which includes viral or non-viral vector. The most popular viral vectors used in gene therapy include adeno-associated viral (AAV), adenovirus, lentivirus, and retrovirus. Similarly, non-viral vectors mainly rely on delivery of plasmid DNA.

Celsion Corporation announced final clinical and translational data on OVATION study at American Association for Cancer Research (AACR) in 2017. Celsion developed standard neoadjuvant chemotherapy with IL-12 DNA plasmid vector as a non-viral delivery system, which is formulated in nanoparticle - GEN-1. It is designed to treat patients with advance stage (III/IV) of ovarian cancers. The DNA-based immunotherapy GEN-1 plus IL-12 showed positive results in clinical trial phase 1b by causing sustained local production and secretion of IL-12 protein at tumor site.

Download FREE PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/962

Researchers - R. Jude Samulski from University of North Carolina and Anamaria C. Sanchez from University of Chile, 2017, developed a gene therapy to treat alcoholism by using short hairpin RNA (shRNA), which is delivered in livers using viral vector – adeno-associated viral (AAV). This is expected to help in prevention of liver enzyme expression that is mainly involved in metabolizing process of conversion of ethanol into acetate.

Moreover, Inovio pharmaceutical, 2017, developed synthetic plasmid DNA-based dMAb monoclonal antibody (mAb) technology for multiple influenza A and B virus strains. The dMAb is expected to trigger cells to activate desired antibodies by utilizing synthetic plasmid, which will encode sequences for cross-protective anti-influenza monoclonal antibodies. This approach is expected to allow rapid responses to unpredicted seasonal flu strains satisfying specific needs of the peoples, including geriatrics, pediatrics, and immune-compromised patients.

The growth of viral vectors and plasmid DNA manufacturing market is attributed to increased fund for gene therapy research, which is a major market driver. For instance, Alliance for Cancer Gene Therapy (ACGT) is a public charity foundation in the U.S, which funds for advancement in cancer gene therapies from laboratory to clinical trials.

The major key players in viral vectors and plasmid DNA manufacturing market includes Celsion Corporation, Inovio pharmaceutical, Lonza, Novasep, FinVector Vision Therapies, Cobra Biologics, Sigma-Aldrich Co. LLC, Biotech GmbH, and Kaneka and Corporation (Eurogentec).

Get FREE Request Sample Copy Of This Business Report:
https://www.coherentmarketinsights.com/insight/request-sample/962

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.